UBS Group’s Meihua International Medical Technologies MHUA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-24
| Closed | -$858 | – | 10925 |
|
|
2025
Q3 | $858 | Sell |
24
-913
| -97% | -$37.3K | ﹤0.01% | 9516 |
|
|
2025
Q2 | $37.5K | Buy |
937
+74
| +9% | +$2.73K | ﹤0.01% | 8015 |
|
|
2025
Q1 | $28.9K | Buy |
863
+240
| +39% | +$7.92K | ﹤0.01% | 7971 |
|
|
2024
Q4 | $21.5K | Sell |
623
-674
| -52% | -$41.3K | ﹤0.01% | 7821 |
|
|
2024
Q3 | $132K | Buy |
1,297
+1,070
| +471% | +$98.1K | ﹤0.01% | 6163 |
|
|
2024
Q2 | $19.4K | Buy |
+227
| New | +$16.3K | ﹤0.01% | 7329 |
|
|
2024
Q1 | – | Sell |
-2
| Closed | -$223 | – | 9754 |
|
|
2023
Q4 | $223 | Buy |
2
+1
| +100% | +$184 | ﹤0.01% | 8793 |
|
|
2023
Q3 | $230 | Sell |
1
-6
| -86% | -$1.63K | ﹤0.01% | 8676 |
|
|
2023
Q2 | $1.88K | Buy |
7
+6
| +600% | +$2.12K | ﹤0.01% | 7843 |
|
|
2023
Q1 | $441 | Sell |
1
-24
| -96% | -$39.6K | ﹤0.01% | 9034 |
|
|
2022
Q4 | $20.6K | Buy |
25
+10
| +67% | +$8.41K | ﹤0.01% | 7623 |
|
|
2022
Q3 | $9K | Buy |
+15
| New | +$6.85K | ﹤0.01% | 8583 |
|
UBS Group's MHUA Position: Q4 2025 in Review
UBS Group sold out of Meihua International Medical Technologies (MHUA) in Q4 2025, closing a stake of 24 shares — an estimated $858 sold.
UBS Group first reported a position in MHUA in Q3 2022 and held it in 12 quarters. The position peaked at $132K in Q3 2024. 0 funds tracked by Wall St. Rank hold MHUA as of Q4 2025.
- UBS Group reported no remaining Meihua International Medical Technologies position as of Q4 2025 after selling out during the quarter.
- UBS Group sold 24 Meihua International Medical Technologies shares in Q4 2025, an estimated $858.
- UBS Group first reported a position in Meihua International Medical Technologies in Q3 2022 and held it in 12 quarters.
- UBS Group's Meihua International Medical Technologies position peaked at $132K in Q3 2024.
- 0 funds tracked by Wall St. Rank held Meihua International Medical Technologies as of Q4 2025.
Based on UBS Group's 13F filing for Q4 2025, filed 29 Jan 2026.